Monument Capital Management Sells 15,679 Shares of Gilead Sciences, Inc. $GILD

Monument Capital Management cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 56.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,267 shares of the biopharmaceutical company’s stock after selling 15,679 shares during the quarter. Monument Capital Management’s holdings in Gilead Sciences were worth $1,550,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL bought a new position in shares of Gilead Sciences in the fourth quarter worth $25,000. Vermillion & White Wealth Management Group LLC boosted its stake in Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 85 shares during the period. Quattro Advisors LLC purchased a new position in Gilead Sciences during the fourth quarter worth about $26,000. Wealth Preservation Advisors LLC grew its position in Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 81 shares in the last quarter. Finally, Wilkerson Advisory Group LLC increased its stake in Gilead Sciences by 54.2% in the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 78 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Strong Q2 operating trends: Analysts highlighted continued year-over-year sales growth led by Biktarvy and the HIV prevention franchise. Quarterly PrEP sales reportedly doubled to more than $1 billion, while Trodelvy and Livdelzi contributed to growth in oncology and liver disease. 5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
• Positive Sentiment: AI oncology collaboration: Gilead partnered with Nucleai to apply AI-powered tissue analytics to its antibody-drug conjugate programs. The technology could accelerate biomarker discovery and support more precise development of Gilead’s oncology pipeline. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Partnership and pipeline optionality: Gilead’s collaboration with Merck is being viewed as a potential growth engine, with recent clinical and regulatory progress supporting the strategic value of combining the companies’ capabilities. Could Merck and Gilead’s Partnership Create the Next Big Pharma Growth Engine
• Positive Sentiment: Assembly Biosciences collaboration: Assembly expanded development of ABI-6250 and reported a $115 million financing, while its cash runway includes a Gilead collaboration extension. The update supports continued advancement of programs associated with Gilead’s partnership. Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
• Positive Sentiment: Analyst and options signals: Analysts cited a consensus price target of $158.04, above the recent trading level, while unusually high call-option activity reflected increased bullish interest. Investors Purchase High Volume of Gilead Sciences Call Options Gilead Receives Consensus Target Price
• Neutral Sentiment: Valuation remains a debate: Despite a substantial multiyear return, commentary suggests Gilead still appears reasonably valued based on sales, leaving room for further gains if growth initiatives continue. Gilead Stock Still Looks Cheap on Sales
• Negative Sentiment: Mixed earnings-estimate revisions: Erste Group Bank modestly reduced its FY2026 EPS forecast to $(0.75) from $(0.74), below the broader consensus estimate of $(0.53), signaling some caution around near-term profitability. Erste Group Bank Estimates Gilead Sciences FY2027 Earnings

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer directly owned 171,646 shares in the company, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the transaction, the chief executive officer directly owned 617,567 shares in the company, valued at approximately $81,185,357.82. This represents a 2.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 51,000 shares of company stock worth $6,568,860 over the last ninety days. Insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on GILD. Truist Financial lowered their price target on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Rothschild & Co Redburn cut their price objective on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Weiss Ratings cut shares of Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a research report on Tuesday. Royal Bank Of Canada raised their target price on shares of Gilead Sciences from $120.00 to $123.00 and gave the company a “sector perform” rating in a research note on Wednesday, August 5th. Finally, Wall Street Zen lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Twenty-four analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $158.04.

Gilead Sciences Trading Up 1.7%

Shares of GILD stock opened at $138.14 on Friday. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The business has a 50-day moving average price of $129.93 and a two-hundred day moving average price of $136.44. Gilead Sciences, Inc. has a 12-month low of $108.46 and a 12-month high of $157.29. The firm has a market cap of $171.29 billion, a P/E ratio of -51.74 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating the consensus estimate of ($7.25) by $0.50. The firm had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company’s revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the company earned $2.01 EPS. Equities analysts anticipate that Gilead Sciences, Inc. will post -0.53 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.4%. Gilead Sciences’s dividend payout ratio is currently -122.85%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.